Genetic variation associated with longer telomere length increases risk of chronic lymphocytic leukemia

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 7, 2016, Pages 1043-1049

  Ojha, Juhi ^a   Codd, Veryan ^b,c   Nelson, Christopher P ^b,c   Samani, Nilesh J ^b,c   Smirnov, Ivan V ^a   Madsen, Nils R ^a   Hansen, Helen M ^a   De Smith, Adam J ^a   Bracci, Paige M ^a   Wiencke, John K ^a,d   Wrensch, Margaret R ^a,d   Wiemels, Joseph L ^a,d   Walsh, Kyle M ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c GLENFIELD HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYP2 GENE; ARTICLE; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CTC1 GENE; GENE; GENETIC ASSOCIATION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; LEUKEMOGENESIS; LEUKOCYTE TELOMERE LENGTH; MAJOR CLINICAL STUDY; NAF1 GENE; OBFC1 GENE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RTEL1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE HOMEOSTASIS; TERC GENE; TERT GENE; ZNF208 GENE; ADULT; AGED; CASE CONTROL STUDY; CLINICAL TRIAL; FEMALE; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; LEUKOCYTE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR;

TUMOR MARKER;

ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TELOMERE HOMEOSTASIS;

EID: 84977127263     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-1329     Document Type: Article

References (42)

1. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497-506
2. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799-804
3. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, et al. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia 2009;23:1062-72
4. Rampazzo E, Bonaldi L, Trentin L, Visco C, Keppel S, Giunco S, et al. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica 2012;97:56-63
5. Blackburn EH. Walking the walk from genes through telomere maintenance to cancer risk. Cancer Prev Res (Phila) 2011;4:473-5
6. Walsh KM, Rice T, Decker PA, Kosel ML, Kollmeyer T, Hansen HM, et al. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: Evidence for distinct pathways of gliomagenesis. Neuro Oncol 2013;15:1041-7
7. Hoxha M, Fabris S, Agnelli L, Bollati V, Cutrona G, Matis S, et al. Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. Genes Chromosomes Cancer 2014;53: 612-21
8. Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: Evidence for a telomere crisis. Blood 2010;116: 1899-907
9. Lin TT, Norris K, Heppel NH, Pratt G, Allan JM, Allsup DJ, et al. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. Br J Haematol 2014;167:214-23
10. Dos Santos P, Panero J, Palau Nagore V, Stanganelli C, Bezares RF, Slavutsky I. Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia. Tumour Biol 2015;36: 8317-24
11. Mirabello L, Yu K, Kraft P, De Vivo I, Hunter DJ, Prescott J, et al. The association of telomere length and genetic variation in telomere biology genes. Hum Mutat 2010;31:1050-8
12. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet 2013;45:422-7, 7e1-2
13. Mangino M, Hwang SJ, Spector TD, Hunt SC, Kimura M, Fitzpatrick AL, et al. Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. Hum Mol Genet 2012;21: 5385-94
14. Berndt SI, Skibola CF, Joseph V, Camp NJ, Nieters A, Wang Z, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet 2013;45:868-76
15. Speedy HE, Di Bernardo MC, Sava GP, Dyer MJ, Holroyd A, Wang Y, et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat Genet 2014;46:56-60
16. Zaitlen N, Kraft P. Heritability in the genome-wide association era. Hum Genet 2012;131:1655-64
17. Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, et al. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget 2015;6:42468-77
18. IlesMM,Bishop DT, Taylor JC, Hayward NK, Brossard M, Cust AE, et al. The effect on melanoma risk of genes previously associated with telomere length. J Natl Cancer Inst 2014;106
19. Zhang C, Doherty JA, Burgess S,Hung RJ, Lindstrom S, Kraft P, et al. Genetic determinants of telomere length and risk of common cancers: AMendelian randomization study. Hum Mol Genet 2015;24:5356-66
20. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7
21. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven commondiseases and 3,000 shared controls. Nature 2007;447:661-78
22. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-9
23. Ouillette P, Collins R, Shakhan S, Li J, Peres E, Kujawski L, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 2011;118:3051-61
24. Gunnarsson R,Mansouri L, Isaksson A, GoranssonH, Cahill N, JanssonM, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 2011;96:1161-9
25. Ouillette P, Malek S. Acquired genomic copy number aberrations in CLL. Adv Exp Med Biol 2013;792:47-86
26. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009;5:e1000529
27. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, et al. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061-73
28. Marchini J, Howie B. Genotype imputation for genome-wide association studies. Nat Rev Genet 2010;11:499-511
29. Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res 1998;58:4918-22
30. Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N, et al. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol 2013;88:647-51
31. EastonDF, Eeles RA. Genome-wide association studies in cancer.HumMol Genet 2008;17:R109-15
32. Hosnijeh FS, Matullo G, Russo A, Guarrera S, Modica F, Nieters A, et al. Prediagnostic telomere length and risk of B-cell lymphoma-Results from the EPIC cohort study. Int J Cancer 2014;135:2910-7
33. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1991;7Suppl 3:9-12
34. Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease. Eur Heart J 2014;35:1917-24
35. De Semir D, Nosrati M, Li S, Kashani-Sabet M. Telomerase: Going beyond the ends. Cell Cycle 2007;6:546-9
36. Chen LY, Redon S, Lingner J. The human CST complex is a terminator of telomerase activity. Nature 2012;488:540-4
37. Brewer JD, Shanafelt TD, Call TG, Cerhan JR, Roenigk RK, Weaver AL, et al. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia. Int J Dermatol 2015;54:e287-93
38. Famenini S, Martires KJ, Zhou H, Xavier MF, Wu JJ. Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. J Am Acad Dermatol 2015;72:78-84
39. Walsh KM, Wiencke JK, Lachance DH, Wiemels JL, Molinaro AM, Eckel-Passow JE, et al. Telomere maintenance and the etiology of adult glioma. Neuro Oncol 2015;17:1445-52
40. Holt SE, Shay JW, Wright WE. Refining the telomere-telomerase hypothesis of aging and cancer. Nat Biotechnol 1996;14:836-9
41. Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 2014;46:731-5
42. Sellmann L, de Beer D, Bartels M, Opalka B, Nuckel H, Duhrsen U, et al. Telomeres and prognosis in patients with chronic lymphocytic leukaemia. Int J Hematol 2011;93:74-82